Source: Annual Congress 2009 - Cell biology of lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Arfkhanova, N. Zoirova (Tashkent, Uzbekistan). Prevention of fibrosis occurrence with melatonin in experiment. Eur Respir J 2009; 34: Suppl. 53, 2850

Member's Comments

No comment yet.

Related content which might interest you: Prevention of asthma development Source: International Congress 2019 – Paediatric Year in review Year: 2019 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Preventive effect of melatonin on bleomycin-induced lung fibrosis in rats Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Impact of non-alcoholic fatty liver disease on late cardiovascular events and death in Chronic Obstructive Pulmonary Disease Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 Prevention of pleural infection Source: International Congress 2019 – Respiratory infections: prevention is better than cure Year: 2019 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Prevention and treatment of sleep disturbances in acute respiratory failure: the role of drugs Source: International Congress 2014 – PG11 Sleep and acute respiratory failure (ARF) Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016 Influenza infection affects the degree of fibrosis and apoptosis in the bleomycin mouse model Source: Annual Congress 2013 –Interesting research questions Year: 2013 Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in Eastern Finland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Protective effects of Dengzhanshengmai capsules on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2014 – ILDs 3 Year: 2014 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Effects of limb training in symptomatic patients with interstitial lung disease of different severity and etiology: A pilot study Source: International Congress 2014 – Best posters in pulmonary rehabilitation 2 Year: 2014 The 2000 steps a day challenge: A tailored exercise programme for lung fibrosis patients Source: International Congress 2014 – Latest insights in physical activity, exercise testing and muscles Year: 2014